PFE Pfizer Inc.

All PFE filings Filing statistics SEC Website

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Company profile

Ticker

PFE

Exchange

NYSE

CEO

Albert Bourla

Incorporated in

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Health Technology > Pharmaceuticals: Major

Industry (SEC)

Pharmaceutical Preparations

Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries • Abbott Laboratories • Bristol Myers Squibb • AbbVie • Mylan • Celgene • Endo International • Elanco Animal Health ...

SEC CIK

0000078003

Corporate docs

Articles of Incorporation & Bylaws

PFE stock data

S&P 500 1 month 1 year

Company financial data Financial data

Chart PFE financial data

Download latest Excel data (2019 Q2) View latest Excel data (2019 Q2)

Quarter (USD)	Jun 19	Mar 19	Dec 18	Sep 18
Revenue	13.26B	13.12B	13.98B	13.3B
Net income	5.05B	3.88B	-393M	4.11B
Diluted EPS	0.89	0.68	-0.05	0.69
Net profit margin	38.04%	29.61%	-2.81%	30.94%
Operating income*	4.52B	4.68B	-588M	4.48B
Net change in cash	-153M	798M	-2.42B	855M
Cash on hand	1.78B	1.94B	1.14B	3.56B
Cost of revenue	2.58B	2.43B	3.08B	2.69B

Annual (USD)	Dec 18	Dec 17	Dec 16	Dec 15
Revenue	53.65B	52.55B	52.82B
Net income	11.15B	21.31B	7.22B	6.96B
Diluted EPS	1.87	3.52	1.17	1.11
Net profit margin	20.79%	40.55%	13.66%
Operating income*	13.17B	13.53B	9.51B	10.14B
Net change in cash	-203M	-1.25B	-1.05B	298M
Cash on hand	1.14B	1.34B	2.6B	3.64B
Cost of revenue	11.25B	11.23B	12.32B	9.65B

Financial data from Pfizer earnings reports. *Asterisk values are approximate.

Financial report summary

Competition

Akorn • TherapeuticsMD • GT Biopharma • Church & Dwight • Teligent • Cypress Bioscience • Celldex Therapeutics • Poniard Pharmaceuticals • Imclone Systems • Acura Pharmaceuticals

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: AA, acid, andNew, Array, Aurobindo, boxed, bridge, CDK, cervical, cognitive, Colorado, conclusion, confirmed, consumption, contemplated, coupon, CreditWatch, decade, dilated, dual, Endothelial, enterprise, equate, excellence, formation, FORMSFOR, FTC, glioblastoma, hepatocellular, Hurricane, Inline, instance, Lamin, Les, lungcancer, lymphocytic, lymphoma, Maria, mCRC, microscopic, mitigate, notably, notch, NRDL, obligor, opioid, page, patientswith, pembrolizumab, potency, Presidential, pro, protein, rata, RCC, RESET, SAS, secondary, selectin, simultaneously, SmPC, strongest, symptomatic, TEC, thehead, transform, triple, underwritten, Vascular, VEGFR, vigorously, wholly, XBRL

Removed: accompanied, adenocarcinoma, agent, aggressively, alfa, Amgen, antirheumatic, Apixaban, appealing, Asian, bleeding, Blueprint, bolivar, closely, communicate, communicated, consistent, conventional, de, death, DICOM, divested, EEA, epoetin, Epogen, exert, filgrastim, gastric, gastroesophageal, head, improvement, inadequate, Inspector, intolerant, limiting, long, medicinal, methotrexate, mixed, moderately, Neupogen, neuromuscular, neuroscience, observed, occurred, ovarian, overexpressing, Panel, partner, pharmacy, priced, Procrit, publish, RAR, recover, reducing, released, revalue, talazoparib, tanezumab, Trump, vehicle, vote, wrongful

From filing 10-Q 2019 Q2